Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

Cancer Discovery

Volumn 3, Issue 4, 2013, Pages 430-443

  Sang, Jim ^a   Acquaviva, Jaime ^a   Friedland, Julie C ^a   Smith, Donald L ^a   Sequeira, Manuel ^a   Zhang, Chaohua ^a   Jiang, Qin ^c   Xue, Liquan ^c   Lovly, Christine M ^d   Jimenez, John Paul ^a   Shaw, Alice T ^b   Doebele, Robert C ^g   He, Suqin ^a   Bates, Richard C ^a   Ross Camidge, D ^g   Morris, Stephan W ^e,f   El Hariry, Iman ^a   Proia, David A ^a  

^a Synta Pharmaceuticals Corp   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e Insight Genetics   (United States)

^f Morris Laboratories HealthChart LLC   (United States)

^g UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CRIZOTINIB; GANETESPIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; P CADHERIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; UVOMORULIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERANCE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR REGRESSION; WESTERN BLOTTING;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84877679409     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0440     Document Type: Article

References (48)

1. Horn L, Pao W. EML4-ALK: honing in on a new target in non-smallcell lung cancer. J Clin Oncol 2009; 27: 4232-5.
2. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011; 61: 91-112.
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identifi cation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
4. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, et al. Identifi cation of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68: 4971-6.
5. Sasaki T, Janne PA. New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011; 17: 7213-8.
6. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012; 9: 268-77.
7. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-12.
8. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011; 108: 7535-40.
9. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, et al. Crizotinib-resistant mutants of EML4-ALK identifi ed through an accelerated mutagenesis screen. Chem Biol Drug Des 2011; 78: 999-1005.
10. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-82.
11. Ardini E, Galvani A. ALK inhibitors, a pharmaceutical perspective. Front Oncol 2012; 2: 17.
12. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.
13. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
14. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-49.
15. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005; 65: 6401-8.
16. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270: 24585-8.
17. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 10686-91.
18. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 2001; 276: 3702-8.
19. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010; 70: 9827-36.
20. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011; 30: 2581-6.
21. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007; 13: 1625-9.
22. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009; 15: 9-14.
23. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profi le for cancer therapy. Mol Cancer Ther 2012; 11: 475-84.
24. Wong K, Koczywas M, Goldman JW, Paschold EH, Horn L, Blackman RK, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29: 2011 (suppl; abstr 7500).
25. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011; 71: 4920-31.
26. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements defi ne a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-70.
27. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identifi cation of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18: 382-4.
28. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-81.
29. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-43.
30. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defi ned non-small-cell lung cancer. J Clin Oncol 2010; 28: 4953-60.
31. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefi tinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
32. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefi tinib. N Engl J Med 2005; 352: 786-92.
33. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242-9.
34. Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012; 4: 2-120.
35. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-60.
36. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012; 18: 6219-26.
37. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res 2012; 18: 3592-602.
38. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005; 11: 8686-98.
39. Andl CD, Rustgi AK. No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther 2005; 4: 28-31.
40. Ou SH. Crizotinib: a novel and fi rst-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011; 5: 471-85.
41. Kiromitsu S, Mori M, Shimada I, Kondoh Y, Nobuaki S, Soga T, et al. Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. Mol Cancer Ther 10: 2011 (suppl; abstr A227).
42. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679-90.
43. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, e t al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identifi cation of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18: 4449-57.
44. Stumpfova M, Janne PA. Zeroing in on ROS1 rearrangements in non-small cell lung cancer. Clin Cancer Res 2012; 18: 4222-4.
45. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-7.
46. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE 2011; 6: e18552.
47. von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J. A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 2005; 4: 400-6.
48. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-88.